The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Remicade (Infliximab) and Biosimilar Market Research Report 2024

Global Remicade (Infliximab) and Biosimilar Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739064

No of Pages : 69

Ask Your Query

Synopsis
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

Global Remicade (Infliximab) and Biosimilar market is projected to reach US$ 3855 million in 2029, increasing from US$ 2550 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Remicade (Infliximab) and Biosimilar market research.

Key manufacturers engaged in the Remicade (Infliximab) and Biosimilar industry include J & J, Pfizer, Organon and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Remicade (Infliximab) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Remicade (Infliximab) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Remicade (Infliximab) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • J & J
  • Pfizer
  • Organon
  • Amgen

Segment by Type

  • Brand
  • Biosimilar

Segment by Application

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Remicade (Infliximab) and Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Remicade (Infliximab) and Biosimilar Market Overview
1.1 Product Overview and Scope of Remicade (Infliximab) and Biosimilar
1.2 Remicade (Infliximab) and Biosimilar Segment by Type
1.2.1 Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) and Biosimilar Segment by Application
1.3.1 Global Remicade (Infliximab) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) and Biosimilar Revenue 2018-2029
1.4.2 Global Remicade (Infliximab) and Biosimilar Sales 2018-2029
1.4.3 Global Remicade (Infliximab) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) and Biosimilar Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Remicade (Infliximab) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Remicade (Infliximab) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
2.7 Remicade (Infliximab) and Biosimilar Market Competitive Situation and Trends
2.7.1 Remicade (Infliximab) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Remicade (Infliximab) and Biosimilar Players Market Share by Revenue
2.7.3 Global Remicade (Infliximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Remicade (Infliximab) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Remicade (Infliximab) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Remicade (Infliximab) and Biosimilar Global Remicade (Infliximab) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2024-2029
3.3 Global Remicade (Infliximab) and Biosimilar Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Remicade (Infliximab) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Remicade (Infliximab) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Corporation Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Corporation Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) and Biosimilar Industry Chain Analysis
7.2 Remicade (Infliximab) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) and Biosimilar Production Mode & Process
7.4 Remicade (Infliximab) and Biosimilar Sales and Marketing
7.4.1 Remicade (Infliximab) and Biosimilar Sales Channels
7.4.2 Remicade (Infliximab) and Biosimilar Distributors
7.5 Remicade (Infliximab) and Biosimilar Customers
8 Remicade (Infliximab) and Biosimilar Market Dynamics
8.1 Remicade (Infliximab) and Biosimilar Industry Trends
8.2 Remicade (Infliximab) and Biosimilar Market Drivers
8.3 Remicade (Infliximab) and Biosimilar Market Challenges
8.4 Remicade (Infliximab) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock
This site is protected by VikingCloud's Trusted Commerce program